ASH 2023 | Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the optimal sequencing patterns for CAR T-cells and bispecific antibodies in the treatment of non-Hodgkin Lymphoma (NHL). Currently, CAR-T is administered before bispecifics, although this is more ambiguous when treating follicular lymphoma (FL). Dr Phillips predicts that bispecifics will move into earlier lines of therapy in the future. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, AstraZeneca, Bayer, Beigene, BMS, Cardinal Health, Epizyme, Incyte, Karyopharm, Pharmacyclics, Seattle Genetics
Research Funding: Abbvie, Bayer
